Galapagos Model update
Galapagos began 2024 with the completion of the transfer of the Jyseleca business to Alfasigma for € 50m upfront, € 120m in milestones and mid-single to mid-double digit royalties. This is expected to result in cost savings for Galapagos, and the company guides for FY24 cash burn of € 280-320m, coming in lower vs. FY23's € 415m. We update our model post FY23, replacing Jyseleca sales with royalties and milestones, and adjust our OPEX estimates to reflect the anticipated cost savings, landing at a new TP of € 50 (from € 55). We continue to believe in the potential of the Cocoon to expand CAR-T access, but are also keen to see an acceleration on the M&A front (e.g. mid stage assets) now that the Jyseleca chapter is behind. For now, we reiterate our Accumulate rating.Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.